# Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma

> **NCT01302496** · PHASE2 · COMPLETED · sponsor: **Bart Neyns** · enrollment: 39 (actual)

## Conditions studied

- Malignant Melanoma Stage III
- Malignant Melanoma Stage IV

## Interventions

- **BIOLOGICAL:** TriMix-DC and ipilimumab

## Key facts

- **NCT ID:** NCT01302496
- **Lead sponsor:** Bart Neyns
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2013-10
- **Final completion:** 2017-01
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302496, "Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01302496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*